VERU INC. VERU

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

We are a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of cardiometabolic and inflammatory diseases. Our drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator ("SARM"), is being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass. This activity leads to improved body composition and physical function with expected clinically meaningful incremental weight reduction versus GLP-1 RA monotherapy. Sabizabulin, a microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease. On December 30, 2024, the Company sold its FDA-approved commercial product, the FC2 Female Condom® (Internal Condom), for the dual protection against unplanned pregnancy and sexually transmitted infections (the "FC2 Business").

Last close 2.24 2026-10-23
Market cap $38.2M 2026-06-30 share count
52-week range 2.05 - 7.33

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue —$16.9M$16.3M$39.4M$61.3M$42.6M$31.8M$15.9M$13.7M$22.1M
Cost of revenue —$11.0M$8.7M$8.8M$13.3M$11.8M$10.1M$7.1M$6.6M$8.8M
Gross profit —$5.9M$7.6M$30.6M$47.9M$30.8M$21.7M$8.8M$7.0M$13.3M
R&D $15.6M$12.8M$51.2M$70.9M$32.7M$16.9M$13.7M$10.9M$3.1M$99.4K
SG&A $19.9M$24.6M$48.1M$43.2M$20.7M$14.5M$14.3M$14.8M$11.5M$8.7M
Total operating expenses $35.5M$37.4M$107.1M$114.1M$53.4M$31.4M$28.1M$29.6M$15.5M$10.3M
Operating income -$24.8M-$36.2M-$93.8M-$83.5M$13.0M-$14.7M-$6.4M-$20.9M-$8.5M$3.0M
Interest expense —$607.5K$2.4M$4.4M$4.9M$4.6M$4.7M$3.0M——
Pre-tax income -$22.7M-$37.8M-$92.7M-$83.8M$4.3M-$20.1M-$12.3M-$23.1M-$8.6M$2.8M
Income tax $0$0$480.2K$236.4K$3.1M$1.1M$303.9K$866.1K$2.0M$2.5M
Net income -$22.7M-$37.8M-$93.2M-$84.0M$7.4M-$19.0M-$12.0M-$23.9M-$6.6M$344.7K
EPS, basic -1.55-2.80-1.10-1.050.10-0.28——-0.250.01
EPS, diluted ——-1.10-1.050.09-0.28-0.19-0.44-0.250.01
Shares, diluted (wtd. avg.) 14.6M13.5M85.0M80.1M83.8M66.8M——34.6M28.9M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $15.8M$24.9M$9.6M———————
Receivables —$4.0M$4.5M$3.6M$8.8M$5.2M$5.0M$4.0M$3.4M$10.8M
Inventory —$4.1M$6.7M$8.6M$5.6M$6.7M$3.6M$2.3M$2.8M$2.5M
Total current assets $18.9M$35.2M$22.9M$104.0M$151.8M$27.0M$16.8M$11.2M$10.3M$16.3M
Property, plant and equipment $364.8K$481.4K$1.7M$1.2M$592.6K$312.7K$351.9K$404.6K$555.5K$825.1K
Goodwill $6.9M$6.9M$6.9M$6.9M$6.9M$6.9M$6.9M$6.9M$6.9M—
Other intangibles —$0$6.0K$4.0M$4.0M$5.8M$20.2M$20.5M$20.8M—
Total assets $29.8M$60.4M$50.0M$135.4M$178.1M$51.5M$53.6M$48.5M$55.3M$38.6M
Accounts payable $3.1M$2.3M$12.9M$22.0M$3.4M$2.8M$3.1M$3.2M$2.7M$701.0K
Total current liabilities $7.8M$11.9M$17.8M$38.7M$15.8M$14.7M$14.0M$13.6M$5.5M$3.3M
Long-term debt ———————$1.8M——
Total liabilities $11.5M$28.1M$30.3M$52.6M$25.9M$21.4M$21.3M$19.0M$6.9M$4.7M
Retained earnings -$317.3M-$294.6M-$256.8M-$163.6M-$81.8M-$89.2M-$70.2M-$58.2M-$34.3M-$27.7M
Total equity $18.3M$32.3M$19.7M$82.8M$154.5M$30.1M$32.3M$29.5M$48.5M$33.9M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$30.0M-$21.7M-$88.0M-$47.5M-$15.6M-$1.9M-$5.5M-$11.5M$982.9K-$1.7M
Depreciation and amortisation $152.1K$268.2K$269.9K$138.0K$98.0K$146.0K—$176.8K$334.0K$422.9K
Stock-based compensation $8.1M$13.6M$17.9M$11.2M$5.1M$2.6M$1.9M$1.6M$756.3K$499.9K
Capital expenditure $1.1K$158.3K$665.7K$733.1K$376.6K$105.8K$108.5K$50.7K$133.5K$6.4K
Investing cash flow $25.1M$146.2K$6.3M$4.3M$14.6M-$105.8K-$108.5K-$50.7K-$90.4K-$6.4K
Financing cash flow -$4.2M$36.8M$11.1M$1.1M$109.7M$9.3M$8.1M$12.1M——

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001437749-25-038089.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -100M -50M 0 50M 100M Revenue, FY2016: 22.1M Gross profit, FY2016: 13.3M Net income, FY2016: 344.7K Revenue, FY2017: 13.7M Gross profit, FY2017: 7M Net income, FY2017: -6.6M Revenue, FY2018: 15.9M Gross profit, FY2018: 8.8M Net income, FY2018: -23.9M Revenue, FY2019: 31.8M Gross profit, FY2019: 21.7M Net income, FY2019: -12M Revenue, FY2020: 42.6M Gross profit, FY2020: 30.8M Net income, FY2020: -19M Revenue, FY2021: 61.3M Gross profit, FY2021: 47.9M Net income, FY2021: 7.4M Revenue, FY2022: 39.4M Gross profit, FY2022: 30.6M Net income, FY2022: -84M Revenue, FY2023: 16.3M Gross profit, FY2023: 7.6M Net income, FY2023: -93.2M Revenue, FY2024: 16.9M Gross profit, FY2024: 5.9M Net income, FY2024: -37.8M Net income, FY2025: -22.7M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $22.1M $13.7M $15.9M $31.8M $42.6M $61.3M $39.4M $16.3M $16.9M —
Gross profit $13.3M $7.0M $8.8M $21.7M $30.8M $47.9M $30.6M $7.6M $5.9M —
Net income $344.7K -$6.6M -$23.9M -$12.0M -$19.0M $7.4M -$84.0M -$93.2M -$37.8M -$22.7M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Results announced Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Material agreement signed Item 1.01
  • Other event Item 8.01
  • Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%